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Chronic myeloid leukemia (CML), first identi-
fied in 1845 (Bennett, 1845; Virchow, 1845), is 
characterized by the Philadelphia chromosome 
encoding the oncogenic BCR-ABL1 tyrosine 
kinase (Rowley, 1973; de Klein et al., 1982). CML 
develops from a hematopoietic stem cell and 
consequently displays multilineage differentia-
tion potential (Calabretta and Perrotti, 2004).   
If not efficiently treated, CML follows a triphasic 
clinical course with an initial indolent chronic 
phase (CP; 5–15 yr), followed by an intermediate 
accelerated phase and, eventually, a blast crisis of 
myeloid, B lymphoid, or biphenotypic myeloid/
lymphoid lineage (Calabretta and Perrotti, 2004). 
Whereas CML can be effectively treated with 
tyrosine kinase inhibitors (TKIs; e.g., Imatinib) 
for many years in the CP (Druker et al., 2006), 
CML blast crisis is invariably multidrug-resis-
tant and fatal within weeks or months (Druker 
et al., 2001). The majority of patients in lym-
phoid blast crisis acquire secondary genetic lesions, 
some of which are introduced by aberrant activity 
of the AID mutator enzyme (Klemm et al., 2009). 
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Chronic myeloid leukemia (CML) is induced by the oncogenic BCR-ABL1 tyrosine kinase and 
can be effectively treated for many years with tyrosine kinase inhibitors (TKIs). However, 
unless CML patients receive life-long TKI treatment, leukemia will eventually recur; this is 
attributed to the failure of TKI treatment to eradicate leukemia-initiating cells (LICs). 
Recent work demonstrated that FoxO factors are critical for maintenance of CML-initiating 
cells; however, the mechanism of FoxO-dependent leukemia initiation remained elusive. 
Here, we identified the BCL6 protooncogene as a critical effector downstream of FoxO in 
self-renewal signaling of CML-initiating cells. BCL6 represses Arf and p53 in CML cells and 
is required for colony formation and initiation of leukemia. Importantly, peptide inhibition 
of BCL6 in human CML cells compromises colony formation and leukemia initiation in 
transplant recipients and selectively eradicates CD34+ CD38 LICs in patient-derived CML 
samples. These findings suggest that pharmacological inhibition of BCL6 may represent a 
novel strategy to eradicate LICs in CML. Clinical validation of this concept could limit the 
duration of TKI treatment in CML patients, which is currently life-long, and substantially 
decrease the risk of blast crisis transformation.
© 2011 Hurtz et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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central mediator of BCR-ABL1 signaling, we studied a BCR-
ABL1 leukemia mouse model in the context of inducible de-
letion  of  Stat5  (Fig.  S2). This  analysis  showed  that  many 
TKI-induced gene expression changes, including BCL6, are 
in fact Stat5-dependent (Fig. 1 A). TKI-induced gene expres-
sion changes that occurred in a Stat5-independent manner 
involved multiple erythroid lineage transcripts, including hemo-
globins (HBA1, HBB, HBD, and HBE1), erythroid surface 
antigens (CD36 and GYPA), Beatty’s protein (elliptocytosis; 
EPB41), and -aminolevulinate synthase (ALAS2; Fig. 1 A). 
TKI-induced up-regulation of BCL6 in human CML cells 
was confirmed in vitro at the mRNA and protein levels (Fig. 1 
B and D), and other gene expression changes were confirmed 
by quantitative RT-PCR (Fig. S3). In agreement with in vitro 
observations, BCL6 is strongly up-regulated in CML cells 
from patients who were treated with TKI.
The ability to up-regulate BCL6 upon TKI treatment  
is restricted to CD34+ CML cells
CML cells were isolated via leukapheresis from two patients 
in CP, and then sorted for CD34+ CD38 and CD34+ CD38+ 
multilineage progenitors and more mature CD34 CD38 
and CD34 CD38+ transient amplifying cells. Treatment with 
Imatinib for 12 h resulted in strong up-regulation of BCL6 
mRNA levels in the CD34+ CML cells, but not in CD34 
CML cells, regardless of CD38 expression (Fig. 1, E and F). 
These findings indicate that the ability to up-regulate BCL6 
in response to TKI treatment is restricted to cells within the 
pool of CD34+ cells with multilineage potential.
BCL6 is a downstream effector molecule of FoxO factors
Previous work implicated FoxO factors as positive regulator 
of BCL6 (Fernández de Mattos et al., 2004). In agreement 
with this study, we found that FoxO activity is required for 
TKI-induced  BCL6  expression  in  CML  cells  (Fig.  1  G).   
Although AKT-mediated phosphorylation downstream of the 
BCR-ABL1 kinase results in global inactivation of FoxO fac-
tors  (Tran  et  al.,  2002;  Fig.  S1),  the  Pten  phosphatase  is   
required  for  FoxO  activation.  Here,  we  demonstrate  that   
conditional deletion of Pten abrogates the ability of CML-like 
cells  to  up-regulate  BCL6  in  response  to TKI  treatment   
(Fig. 1 G). In fact, overexpression of a constitutively active 
FoxO3A  mutant  was  sufficient  to  induce  an  10-fold   
increase of BCL6 mRNA levels in human CML cells (Fig. 1 H). 
The finding of FoxO3A as upstream regulator of BCL6 is of 
particular importance, given that FoxO3A was recently iden-
tified as a requirement for the maintenance of CML-initiating 
cells (Naka et al., 2010).
BCL6 is required for a basic level of Imatinib-resistance  
in CML cells
We then tested the significance of TKI-induced BCL6 in a 
genetic loss-of-function experiment. To this end, BCL6+/+ 
and BCL6/ bone marrow hematopoietic progenitor cells 
were transformed with p210 BCR-ABL1 according to a clas-
sical model for CML in mice (Pear et al., 1998; Li et al., 1999). 
During blast crisis progression, mutations of the CDKN2A 
(ARF), MYC, RB1, AML1, TP53, and RAS genes are fre-
quently acquired (Melo and Barnes, 2007), and in the major-
ity of CML blast crisis cases, mutations within the BCR-ABL1 
kinase domain encode resistance against TKI treatment (Shah 
et al., 2002).
The development of Imatinib mesylate, a selective BCR-
ABL1 kinase inhibitor, achieved an overall survival of 95% 
over a 5-yr period for CML patients in CP (Druker et al., 
2006). Despite its clinical success, Imatinib fails to eradicate 
CML entirely (Corbin et al., 2011), and in virtually all cases 
residual leukemia-initiating cells (LICs) persist (Kantarjian et al., 
2009). Despite having low numbers, LICs have the capacity to 
reinitiate leukemia, which is typically the case upon discon-
tinuation of TKI treatment (Rousselot et al., 2007). Previous 
works showed that classical pathways of self-renewal signal 
transduction in normal stem cell populations (e.g., WNT/ 
-catenin; Sonic hedgehog) are also required for self-renewal 
signaling in CML-LIC (Zhao et al., 2007; Zhao et al., 2009).
A recent study demonstrated that FoxO factors are critical 
for maintenance of LICs in CML (Naka et al., 2010). FoxO 
activity is negatively regulated by BCR-ABL1–AKT signal-
ing and positively regulated by TKI treatment (e.g., Imatinib; 
Fernández de Mattos et al., 2004) and Pten (Trotman et al., 
2006; Fig. S1). For this reason, the identification of FoxO as a 
critical factor for the maintenance of LICs in CML is of par-
ticular interest, as it provides a direct explanation for how 
CML-initiating cells persist despite long-term TKI treatment. 
The  mechanisms  through  which  FoxO3A  mediates  self- 
renewal and maintenance of CML-initiating cells, however, 
remain unclear.
In this study, we identified the BCL6 transcription factor 
downstream of FoxO as a critical effector molecule for pro-
tection and maintenance of leukemia-initiating cells in CML. 
BCL6 was first identified as a protooncogene in diffuse large 
B cell lymphoma, which is characterized by a high frequency 
of BCL6-IGH translocations (Ye et al., 1995). BCL6 is re-
quired for affinity maturation of mature B cells in germinal 
centers (Dent et al., 1997; Ye et al., 1997), a process that criti-
cally depends on BCL6-mediated transcriptional repression 
of  p53  (Phan  and  Dalla-Favera,  2004).  More  recently,  we 
demonstrated that BCL6 is also critical for pre–B cell survival 
(Duy et al., 2010). Moreover, BCR-ABL1–transformed pre– 
B cell acute lymphoblastic leukemia (Ph+ ALL) cells respond 
to TKI treatment by up-regulation of BCL6. TKI-induced 
up-regulation of BCL6 enables Ph+ ALL cells to survive TKI 
treatment (Duy et al., 2011). This study is focused on myeloid 
lineage  CML  and  widens  the  emerging  role  of  BCL6  in 
BCR-ABL1–driven leukemias.
RESULTS AND DISCUSSION
CML cells up-regulate BCL6 in response to TKI treatment
To study genes potentially contributing to the maintenance 
of CML cells exposed to TKI treatment, CML cells were incu-
bated in the presence or absence of the TKI Imatinib and sub-
jected to gene expression analysis. Because Stat5 represents a JEM Vol. 208, No. 11  2165
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model for BCL6+/+ and BCL6/ hematopoietic progenitor 
cells was established (Fig. S5 and Fig. S6).
Because the pool of CD34+ cells with multilineage po-
tential  represents  the  main  source  of  BCL6  expression  in   
human CML (Fig. 1, E and F), we studied the effect of BCL6 
deficiency in the equivalent population (Lin Sca-1+ c-Kit+ 
[LSK]) in our CML-like mouse model. Given that BCL6 was 
strongly up-regulated in response to Imatinib-treatment of 
CML cells (Fig. 1), we tested whether BCL6 regulates sensi-
tivity of CML cells to Imatinib. Mouse LSK cells in CML-
like leukemia are highly refractory to Imatinib, 
and Imatinib concentrations of >3 mol/liter 
are  required  to  induce  cell  death  in  LSK+ 
CML cells. BCL6-deficient CML LSK cells, 
however, were sensitive to Imatinib even at 
concentrations  <0.5  mol/liter  (Fig.  2 A).   
The transformation efficiency of BCL6+/+ and BCL6/ 
hematopoietic progenitor cells was undistinguishable and, in 
both cases, after 1 wk a growth factor–independent CML-
like leukemia developed (Fig. S4; n = 3). Because BCR-ABL1 
can give rise to both B cell lineage and myeloid lineage leu-
kemia (i.e., CML), a myeloid-specific transformation protocol 
was used in all experiments (Li et al., 1999). Myeloid lineage 
identity of the BCR-ABL1–transformed cells was routinely 
verified by flow cytometry. The phenotype of CML-like cells 
was characterized in depth when the CML-like leukemia 
Figure 1.  Regulation of BCL6 expression in CML 
cells. (A) To identify TKI-regulated genes in human CML 
cells, three human CML cell lines (KCL22, KU812, and 
JURL) were treated with (IM) or without (Ctrl) 1 mol/
liter Imatinib for 16 h and studied in an Affymetrix 
GeneChip analysis. Genes were sorted based on gene 
expression differences between TKI-treated and un-
treated CML cells. Likewise, BCR-ABL1–transformed leu-
kemia cells from Stat5fl/fl bone marrow were transduced 
with Cre or an empty vector control. Gene expression 
values for Stat5fl/fl (Ctrl) and Stat5-deleted (Cre) leukemia 
cells are indicated for the genes identified in TKI-treated 
cells. (B) Affymetrix GeneChip data for BCL6 was vali-
dated by quantitative RT-PCR on three cases of human 
CML (with or without 1 mol/liter Imatinib overnight). 
(C) BCL6 gene expression values for CML cells from six 
patients before and after 7 d of Imatinib-treatment are 
shown (meta-analysis of data from Bruennert et al. 
[2009]). (D) Human CML cells were treated with TKI  
(10 µM for 24 h) and BCL6 expression was evaluated  
by Western blotting using -actin as a loading control.  
(E and F) Leukapheresis samples from two patients with 
CML-CP (CP21 and CP22) were sorted into four subpopu-
lations based on CD34 and CD38 surface expression as 
depicted in the flow cytometry dot plots. Subpopulations 
were incubated overnight in the presence and absence of 
10 µmol/liter Imatinib and then subjected to quantitative 
RT-PCR for BCL6 mRNA levels using COX6B as a refer-
ence gene. For each subpopulation, fold-induction of 
BCL6 mRNA levels are shown (triplicate measurements 
were performed; *, P < 0.05; **, P < 0.01). (G) Ptenfl/fl 
mouse CML cells were transduced with 4-OHT–inducible 
Cre-ERT2 or ERT2 empty vectors. BCL6 protein levels are 
shown after treatment with 4-OHT in the presence or 
absence of Imatinib. Pten deletion in Cre-ERT2–transduced 
cells was verified by Western blot. (H) Human CML cells 
(KCL22) were transduced with a retroviral vector encod-
ing a constitutive active form of FoxO3A (FoxO3aCA CD90) 
or an empty control vector (CD90 EV). CD90+ cells were 
sorted (sort gate indicated) and studied for BCL6 mRNA 
levels by quantitative RT-PCR using COX6B as a reference 
gene. Mean values of three experiments ± SD and  
p-value are indicated.2166 BCL6 is required for leukemia initiation in CML | Hurtz et al.
Pharmacological inhibition of BCL6 sensitizes CML cells  
to TKI treatment
Because the aforementioned genetic experiments indicate a 
critical role for BCL6 in Imatinib resistance of CML cells, we 
next tested if the implicated synthetic lethality could be tar-
geted pharmacologically using a combination of Imatinib and 
a BCL6-peptide inhibitor in human CML cells. To this end, 
human CML cells were incubated in the presence or absence 
of  Imatinib,  a  novel  retro-inverso  BCL6  peptide  inhibitor 
(RI-BPI; Cerchietti et al., 2009), or a combination of both 
(Fig. 2 E). Although RI-BPI alone did not significantly affect 
CML cell viability, it strongly enhanced the effect of Imatinib, 
except for one case, in which nearly all cells underwent apop-
tosis upon Imatinib treatment alone (Fig. 2 E).
Comparing the response of CML-like cells to Imatinib treat-
ment (10 mol/liter), BCL6+/+ CML-like cells were signifi-
cantly less sensitive compared with BCL6/ CML-like cells 
(mean viability 71.8 ± 2.7% compared with 31.4 ± 1.6%   
viable cells; P < 0.0003; Fig. 2 B). We next studied whether 
inducible reconstitution of BCL6 rescues Imatinib-resistance 
in BCL6/ CML-like cells. To this end, BCL6/ CML-like 
cells were transduced with a 4-hydroxy-tamoxifen (4-OHT)–
inducible  BCL6-ER  fusion  molecule,  which  is  activated 
within minutes after 4-OHT addition (Shaffer et al., 2000). 
Although an ER empty vector control had no effect on the 
survival of leukemia cells, inducible BCL6 activation con-
ferred a strong survival advantage as reflected by a 30-fold   
increase of BCL6-ER–transduced cells (Fig. 2, C and D).
Figure 2.  BCL6 is required for a basic level of Imatinib-resistance in CML cells. (A) BCL6/ and BCL6+/+ CML-like cells were treated with Imatinib 
at various concentrations for 3 d, and cell metabolism was measured in a Resazurin assay. Mean values ± SD of three experiments are depicted.  
(B) BCL6+/+ and BCL6/ CML cells were treated with Imatinib as in A, and apoptosis was assessed by flow cytometry analysis of 7AAD and annexin V. 
Mean values ± SD of three experiments are depicted. (C) BCL6/ CML-like cells were transduced with 4-OHT–inducible BCL6 (BCL6-ERT2/GFP) or an  
ERT2/GFP empty vector control. BCL6/ CML-like cells were then treated with 1 mol/liter Imatinib for the times indicated and in the presence of 4-OHT–
mediated induction of BCL6-ERT2 or ERT2. Percentage of GFP+ cells were measured by flow cytometry as an indication of a BCL6-ERT2– or ERT2-mediated 
survival advantage. A time course of mean values ± SD of three experiments is depicted in C, and examples of the flow cytometry plots are shown in D. 
(E) Human CML cell lines (KCL22, JURL, LAMA84, KYO1, and KU812) were incubated in the presence or absence of 1 µmol/liter Imatinib, 5 µmol/liter  
RI-BPI, or a combination of both for 3 d. Viability was measured by flow cytometry. Mean values, SD, and p-values from three experiments are indicated.JEM Vol. 208, No. 11  2167
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molecules  in  BCL6/  CML-like  cells  (e.g.,  Egr1,  Ptgs1, 
Slamf1/CD150, Gfi1, Rora, Abcg2; Fig. S7).
In the absence of BCL6 function, LICs in CML are poised  
to undergo apoptosis
These changes may occur for various reasons, such as en-
hanced  differentiation,  reduced  self-renewal,  or  selective 
apoptosis/depletion of BCL6/ LICs. To test these possibili-
ties, we sorted viable LICs (LSK+ phenotype) and transient 
amplifying cells (LSK phenotype) from freshly generated 
BCL6+/+ and BCL6/ CML-like leukemia. At this time, 
BCL6/ CML-like leukemia still had a high frequency of 
LSK+ cells. For each population, between 100,000 and 1 mil-
lion cells were sorted with >98% viable cells. After 20 h of 
incubation, cell counts moderately increased for transient   
amplifying cells from both BCL6+/+ and 
BCL6/ CML-like leukemia. Also counts 
for LSK+ LICs from BCL6+/+ CML-like 
leukemia  increased,  whereas  counts  for 
LSK+  LICs  from  BCL6/  CML-like 
leukemia significantly dropped (Fig. S8). 
Selective reduction of LSK+ LIC counts 
from  BCL6/  CML-like  leukemia  is 
consistent with LIC depletion observed in 
Fig. 3, A and B. Strikingly, flow cytometry 
BCL6 is required for the maintenance of LSK cells  
in a mouse model for CML
When mouse LSK cells were transformed with BCR-ABL1 
in  the  presence  of  IL-3,  IL-6  and  SCF,  the  vast  majority   
of  BCL6+/+  CML-like  cells  retain  an  LSK-phenotype.  In 
contrast, the LSK population of the BCL6/ CML-like 
cells rapidly undergoes apoptosis. Within 2 wk, the LSK pop-
ulation, which is thought to comprise the pool of LICs was 
reduced from 15 to <1% in BCL6/ CML (Fig. 3, A and B). 
As opposed to LSK cells, the non-LSK population consis-
tently lacks the ability to initiate leukemia in serial transplan-
tation experiments (Hu et al., 2006; Neering et al., 2007;   
Ito et al., 2008; Zhao et al., 2009). Besides loss of the LSK 
phenotype, an Affymetrix GeneChip expression analysis re-
vealed loss of expression of multiple other stem cell–related 
Figure 3.  BCL6 is required for the mainte-
nance of LSK+ cells in CML. (A and B) BCR-ABL1 
transformed CML-like cells from BCL6+/+ and 
BCL6/ bone marrow at 1 and 3 wk after trans-
duction. Cells were gated on Lin phenotype and 
surface expression of Sca-1 and c-Kit (LSK; A) and 
CD44 and c-kit (B) is shown (n = 3). (C) Human 
CML cells (JURL cell line) were subjected to one 
round of ChIP-seq analysis for a genome-wide 
mapping analysis of recruitment of the BCL6 tran-
scription factor. Overlays of input (green) and 
BCL6 ChIP (red) are shown for BCL6 (positive con-
trol; binding to its own promoter), HPRT (negative 
control), DNA damage response and cell cycle 
checkpoint genes including CHEK, CDKN2AIP, 
TP53, CDKN1A (p21), GADD45A, and CDKN2A (Arf). 
Peaks of significant enrichment of BCL6 in pro-
moter regions relative to input were identified by 
ChIPSeeqer (black bars). (D) BCR-ABL1–transformed 
CML-like cells from BCL6+/+ and BCL6/ bone 
marrow were analyzed by Western blot for Arf and 
p53 protein levels using -actin as loading control 
(two experiments are shown). (E) 100,000 BCL6+/+ 
and BCL6/ CML-like cells were plated in semi-
solid methylcellulose agar and colonies were 
counted after 22 d. Chart shows mean values ± SD 
and p-value of 5 experiments. (F) Cell cycle  
analysis of BCL6+/+ and BCL6/ CML cells was 
performed studying BrdU incorporation in combi-
nation with 7AAD staining. Annotations indicate 
distribution of CML-like cells to G0/1, S, and G2/M 
phases of the cell cycle. One representative experi-
ment of three is shown.2168 BCL6 is required for leukemia initiation in CML | Hurtz et al.
revealed  a  striking  anomaly  in  BCL6/  CML-like  cells, 
which  exhibit  a  large  subpopulation  with “mitotic  crisis” 
phenotype (Fig. 3 F; Li and Dang, 1999). BrdU incorpora-
tion  showed arrest in G1/S-phase with incomplete DNA 
replication. Consistent with the high level of DNA damage 
stress and Arf/p53 activation, LSK+ BCL6/ CML cells do 
not survive over longer periods of time. As shown in Fig. 3  
(A and B), >95% of LSK+ BCL6/ CML cells die within   
3 wk of leukemic transformation. In cell culture experiments,   
we observed that BCL6/ CML-like cells occasionally 
ceased  to  propagate  and  the  entire  population  underwent   
cell cycle arrest. In the context of the “mitotic crisis” pheno-
type (Fig. 3 F), we hypothesized that BCL6/ CML-like 
cells may undergo replicative senescence owing to telomere 
shortening  after  multiple  cell  divisions.  Measurement  of 
telomere lengths in BCL6+/+ and BCL6/ CML-like cells 
by  flow  FISH  (Fig.  S10),  however,  showed  that  telomere 
lengths were similar in BCL6+/+ (31.4 ± 1.1 kb) and BCL6/ 
CML-like cells (35.5 ± 0.9 kb).
BCL6-mediated transcriptional repression of p53 enables 
self-renewal of LICs in CML
Because BCL6 functions as a transcriptional repressor of p53 
in human and mouse CML cells (Fig. 3, C and D), we hy-
pothesized that BCL6-mediated repression of p53 represents 
a  key  element  in  BCL6-dependent  self-renewal  signaling.   
To test this hypothesis, we transduced p53+/+ and p53/ 
CML-like cells with a 4-OHT–inducible dominant-negative 
mutant of BCL6 (DN-BCL6-ERT2; Shaffer et al., 2000). This 
form competes with wild-type BCL6 for DNA binding, but 
lacks  the  BCL6-BTB  (Bric-à-Brac, Tramtrack,  and  Broad 
complex)  domain  and  thus  lacks  the  ability  to  function   
as transcriptional repressor. 4-OHT–mediated induction of 
DN-BCL6-ERT2 nearly completely suppressed colony for-
mation in p53+/+ CML-like cells, whereas colony formation 
in p53/ CML-like cells was only slightly reduced (Fig. 4 A). 
Likewise, induction of DN-BCL6-ERT2 induced G1/0 cell 
cycle arrest in p53+/+, but not p53/ CML-like cells (Fig. 4 B). 
In contrast to p53/ CML-like cells, 4-OHT–mediated in-
duction  of  DN-BCL6-ERT2  resulted  in  a  drastic  growth   
disadvantage in p53+/+ CML-like cells (reduction of trans-
duced cells to <20% within 5 d; Fig. 4, C and D). These find-
ings  suggest  that  BCL6-mediated  repression  of  p53  is   
not only required for the initiation of CML colonies (Fig. 4 A), 
but  also  for  the  proliferation  and  survival  of  CML  LICs   
(Fig. 4, B and D).
BCL6 function represents an absolute requirement  
for leukemia initiation in CML
To formally test the requirement of BCL6 for leukemia initiation 
in vivo, we performed a classical SCID leukemia-initiating cell 
(SL-IC) assay (Bonnet and Dick, 1997). 500,000 luciferase- 
labeled BCL6+/+ and BCL6/ CML-like leukemia cells (Lin 
Sca-1+ c-Kit+ CD13+; Fig. S5) were injected intrafemorally into 
NOD/SCID mice, and leukemia initiation and expansion was 
monitored by bioimaging (Fig. 5 A). Intrafemoral injection was 
revealed  that  the  majority  of  LSK+  LICs  from  BCL6/ 
CML-like leukemia was preapoptotic after 20 h. These find-
ings show that BCL6 represents a critical factor for LIC sur-
vival in CML. In the absence of BCL6 function, LICs are 
poised to undergo apoptosis.
BCL6 directly represses p53 and MYC in human CML cells
To identify transcriptional targets of BCL6 in human CML 
cells,  we  performed  a  genome-wide  mapping  analysis  of 
BCL6 recruitment using ChIP-seq. Because BCL6 is known 
to  function  as  its  own  repressor  (Mendez  et  al.,  2008),   
we studied recruitment of BCL6 to the BCL6 and HPRT 
promoters  as  positive  and  negative  controls,  respectively   
(Fig. 3 C). Several molecules in the DNA damage/checkpoint 
signaling pathway, including CHEK1, CARF (CDKN2AIP), 
p53, GADD45A, and p21 (CDKN1A) exhibit robust recruit-
ment of BCL6 (Fig. 3 C). ChIP-seq was not informative for 
ARF, because the JURL CML cells studied carry biallelic   
deletions at 9p21, including the CDKN2A locus (Fig. 3 C). 
CARF (CDKN2AIP), which is required for protein stability 
of ARF (CDKN2A; Hasan et al., 2002), and p53 are both   
direct transcriptional targets of BCL6 (Fig. 3 C). Therefore, 
we tested whether the ARF/p53 pathway is deregulated in 
BCL6/ CML-like cells. Indeed, protein levels of both ARF 
and p53 were increased in the absence of BCL6 (Fig. 3 D). 
Hence, BCL6 may curb excessive expression of ARF/p53   
in CML-like cells.
BCL6 is required for self-renewal of LICs in CML
Because components of the Arf/p53 pathway are mediators of 
cellular  senescence  and  negatively  regulate  self-renewal  in 
normal hematopoiesis and leukemia (Oguro et al., 2006), we 
next tested whether the unrestrained expression of Arf/p53 in 
the absence of BCL6 interferes with CML cell self-renewal. 
To this end, BCL6+/+ and BCL6/ LSK cells from CML-
like leukemia were plated in semisolid agar and colonies were 
counted 22 d later. Immediately before plating, viability of 
cells was verified by flow cytometry (>90%). Strikingly, in the 
absence of BCL6, LSK cells from CML-like leukemia nearly 
entirely lack the ability to form colonies, and on most plates 
not a single colony was detected (Fig. 3 E). In the absence of 
BCL6, colony formation was reduced by >300-fold, which 
demonstrates a critical role of BCL6 in self-renewal of CML-
initiating cells. Unlike for LICs in CML, BCL6 was dispens-
able for colony formation in normal LSK. Although normal 
BCL6/ LSK cells had a slightly lower colony count com-
pared with BCL6+/+ LSK cells, colony formation was not 
compromised in the absence of BCL6 (Fig. S9). Likewise, a 
recent study demonstrated that normal LSK cells from BCL6-
deficient mice have multilineage potential similar to their 
BCL6+/+ counterparts (Broxmeyer et al., 2007). More detailed 
experiments to address a potentially unrecognized function of 
BCL6 in normal LSK cells are currently under way.
Because Arf/p53 signaling also affects cell cycle check 
points, we studied the consequences of BCL6-deficiency on 
cell cycle regulation in CML-like cells (Fig. 3 F). This analysis JEM Vol. 208, No. 11  2169
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Inducible activation of a dominant-negative BCL6 mutant 
suppresses CML leukemogenesis in vivo
We  next  tested  whether  loss-of-function  of  BCL6  also   
affects human CML cells. To this end, human CML cells 
(KCL22 cell line) were transduced with DN-BCL6-ERT2 
or the ERT2 empty vector control, labeled with lentiviral 
firefly  luciferase,  and  injected  into  sublethally  irradiated 
NOD/SCID mice (Fig. 5 B). After visible engraftment of 
CML, NOD/SCID mice were treated with intraperitoneal 
injections of 4-OHT over 3 intervals of 10 d (20 mg/kg 
4-OHT/per day). Consistent with our in vitro observa-
tion, inducible inhibition of BCL6 compromised leukemia 
initiation in vivo (Fig. 5 B) and significantly prolonged 
overall survival of xenografted NOD/SCID mice (Fig. 5 C). 
We conclude that BCL6 function is critical for initiation 
of human CML in vivo.
chosen to focus on leukemia initiation and to exclude potential 
defects in bone marrow homing and engraftment of BCL6/ 
CML-like cells as confounding variables (Krause et al., 2006). 
Although BCL6+/+ LSK cells from CML-like leukemia rapidly 
initiated leukemia, bioimaging revealed persistence of BCL6/ 
LSK cells at the site of injection, but no overt leukemia initiation 
(Fig. 5 A). Our intention was to perform serial transplantation 
experiments to assess leukemia initiation potential of BCL6/ 
CML-like leukemia in secondary or tertiary transplants. Because 
BCL6/ LSK cells failed to initiate leukemia in primary 
transplant recipients, serial transplantation was not possible. 
Consistent with our colony formation assays, the defect of leu-
kemia-development from BCL6/ CML-like cells reflects fail-
ure to maintain leukemia-initiating cells, as exemplified by the 
progressive loss of the LSK+ population in BCL6/ CML-like 
leukemia (Fig. 3, A, B, and E).
Figure 4.  BCL6-mediated transcriptional repression of p53 enables colony formation and proliferation of CML cells. p53+/+ and p53/  
CML-like cells were transduced with a 4-OHT–inducible dominant-negative BCL6 (DN-BCL6-ERT2) or an empty vector control and 100,000 cells each were 
plated in semisolid agar (A). Photomicrographs of methylcellulose plates and statistical analysis are shown. (B) p53+/+ and p53/ CML-like cells trans-
duced with a 4-OHT–inducible dominant-negative BCL6 (DN-BCL6-ERT2) or an empty vector control (ERT2) and cell cycle was analyzed by flow cytometry 
(BrdU and 7AAD staining). FACS plots and statistical analysis are shown. (C and D) p53+/+ and p53/ hematopoietic progenitor cells were transformed 
with BCR-ABL1 to generate CML-like leukemia and then transduced with DN-BCL6-ERT2 or a GFP empty control vector. CML-like cells expressing GFP, 
were incubated in vitro and relative changes of GFP+ percentages were plotted against time (days) after 4-OHT–mediated induction (C). In D, one example 
of flow cytometry measurements over 9 d is shown. Mean values of three experiments ± SD are indicated.2170 BCL6 is required for leukemia initiation in CML | Hurtz et al.
RI-BPI selectively eradicates CD34+ CD38 LICs  
in patient-derived CML samples
To study the effect of acute BCL6 inactivation in patient- 
derived CML cells, we incubated CML cells from 5 patients 
in CP (CP22-CP26; Table S1) and 1 patient in blast crisis 
(BC12; Table S1) in 5 mol/liter RI-BPI or Vehicle for 2 h. 
After this incubation period, RI-BPI was washed out and 
cells were cultured in the presence of 100 ng/ml SCF, 100 
ng/ml G-CSF, 20 ng/ml FLT3, 20 ng/ml IL-3, and 20 ng/ml 
IL-6. In one set of experiments, cells were stained with CFSE 
to track cell divisions over time. Flow cytometry revealed that 
RI-BPI–treated  CML-CP  samples  selectively  lost  CD34+ 
CD38 LICs (Fig. 6, A and B), whereas CD34 subpopula-
tions remained intact (Fig. 6 C). Likewise, RI-BPI caused cell 
cycle arrest in CD34+ CD38 LICs (Fig. 6 B), whereas other 
subpopulations continued to divide as measured by CFSE dye 
dilution. In one case of blast crisis CML, RI-BPI neither   
affected the CD34+ CD38 LIC population nor induced cell 
cycle arrest in CD34+ CD38 LICs. These findings are in 
agreement with cell cycle deregulation of BCL6/ CML-
like cells and suggest that acute inhibition of BCL6 function 
can commit CD34+ CD38 LICs to eradication in CML-CP, 
but not in CML-BC (Fig. 6 C).
BCL6 is a pharmacological target for eradication  
of leukemia-initiating cells in CML
We  next  tested  whether  pharmacological  inhibition  of 
BCL6  (RI-BPI)  can  interfere  with  leukemia  initiation   
in human CML. We performed a colony formation assay 
with human CML cells that were plated on semisolid agar 
plates with vehicle or 5 mol/liter RI-BPI. Consistent with 
our  observation  that  BCL6/  CML-like  cells  nearly   
entirely  lacked  the  ability  to  form  colonies  (Fig.  3  E),   
RI-BPI–mediated inhibition of BCL6 reduced colony num-
bers by three- to eightfold compared with untreated cells in 
a BCL6+/+ context (Fig. 5 D). More importantly, RI-BPI 
also interfered with leukemia initiation of human CML cells 
in vivo. Upon treatment with RI-BPI, xenografted human 
CML cells (KCL22 cell line) failed to initiate leukemia in 
transplant recipients. Treatment of human CML cells with 
RI-BPI  increased  overall  survival  of  recipient  mice  and   
latency of leukemia. 3 of 10 mice that were xenografted 
with human CML cells (KCL22 cell line) in the RI-BPI group 
were sacrificed after 180 d (Fig. 5, E and F) and had no   
indication of leukemia (no CML cells detectable in bone   
marrow and spleen), compared with no such cases in the 
untreated controls.
Figure 5.  BCL6 is required for self- 
renewal and leukemia initiation in CML.  
(A) BCL6/ and BCL6+/+ CML-like cells were 
labeled with firefly luciferase and 500,000 
cells were injected into sublethally irradiated 
NOD/SCID mice (7 mice per group; two inde-
pendent experiments). Engraftment and  
leukemic growth was measured by lucifer-
ase bioimaging at the times indicated.  
(B and C) Human CML cells (KCL22) were trans-
duced with a 4-hydroxy-tamoxifen (4-OHT)-
inducible dominant-negative mutant of BCL6 
(DN-BCL6-ERT2; Shaffer et al., 2000) or an ERT2 
empty vector control (B). Human CML cells 
were labeled with lentiviral firefly luciferase 
and 3 × 106 cells were injected into sub-
lethally irradiated NOD/SCID mice (7 mice per 
group). NOD/SCID recipients were treated  
30 times (3 sets of 10 injections) with tamoxifen 
(20 mg/kg) after leukemia cell were injected 
(second set of treatment was performed after 
34 d, third set of treatment was performed 
after 55 d). Leukemia burden (B) and overall 
survival (Kaplan-Meier analysis; C) are shown 
(two independent experiments). (D) 10,000 
cells from three CML cases were plated in 
semisolid methylcellulose agar with or with-
out RI-BPI (5 µmol/liter). Colonies were 
counted after 10 d. The chart shows mean 
values ± SD and p-value of five experiments. 
(E) 3 × 106 human CML cells (KCL22) labeled with firefly luciferase were treated with or without 5 µmol/liter RI-BPI ex vivo and injected into sublethally 
irradiated NOD/SCID mice. Overall survival, engraftment, and leukemia progression were monitored by Kaplan-Meier analysis (E) and luciferase bioimaging 
(F), respectively. Two separate injections and treatments were performed and 10 mice per group were studied.JEM Vol. 208, No. 11  2171
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initiation from xenografted human CML cells in vivo. Based 
on these findings, we propose a dual targeting strategy, in 
which tyrosine kinase inhibitors (e.g., Imatinib) to target the 
transient amplifying pool of CML cells are coupled with BCL6 
inhibition that will target quiescent LICs. Pharmacological 
options  include  the  BCL6  peptide  inhibitors  used  here   
(Cerchietti et al., 2009) or newly developed small molecule 
inhibitors against BCL6 (Cerchietti et al., 2010). Pharmaco-
logical inhibition of BCL6, thus, represents a fundamentally 
novel strategy to eradicate LICs in CML. Clinical validation 
of this concept could limit the duration of TKI treatment in 
CML patients, which is currently life-long, and potentially 
decrease the risk of blast crisis transformation.
MATERIALS AND METHODS
Patient samples, human cells and cell lines. Patient samples (Table S1) 
were provided from the German CML Study Group (in compliance with the 
internal review board of the University of Southern California Health Sci-
ences Campus, the University of California San Francisco, the Oregon Health 
and Science University, and the Universität Heidelberg Klinikum Mannheim). 
In total, 26 cases of CP CML and 12 cases of CML blast crisis were stud-
ied, and the characteristics of these patients are summarized in Table S1   
(CP1-CP26 and BC1-BC12). The human CML cell lines EM2, JURL-
MK1, KCL22, KU812, KYO, LAMA84, MEG1, and MOLM6 were ob-
tained from the German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany. Human leukemia cells were maintained in RPMI-
1640  (Invitrogen)  with  GlutaMAX  containing  20%  fetal  bovine  serum,   
100 IU/ml penicillin, and 100 µg/ml streptomycin at 37°C in a humidified 
incubator with 5% CO2.
CML-like leukemia model and transplantation experiments. For all 
retroviral transductions with BCR-ABL1, the myeloid-restricted protocol 
described in Li et al. (1999) was used, which   
results in CML-like disease. In brief, bone mar-
row cells were cultured either in Iscove’s modi-
fied Dulbecco’s medium (IMDM; Invitrogen) 
with GlutaMAX containing 20% fetal bovine 
serum, 100 IU/ml penicillin, 100 µg/ml strep-
tomycin, 50 µM 2-mercaptoethanol, 10 ng/ml 
recombinant mouse IL-3, 25 ng/ml recombinant 
mouse IL-6, and 50 ng/ml recombinant mouse 
SCF (PeproTech) or retrovirally transformed by 
Concluding remarks
A recent work identified a critical role for FoxO factors in the 
maintenance of leukemia-initiating cells in CML (Naka et al., 
2010). In this study, we demonstrate that BCL6 functions as 
key  effector  molecule  downstream  of  FoxO  and  prevents 
CML LIC depletion by transcriptional repression of Arf/p53. 
Although Imatinib successfully induces cell death in transient 
amplifying CML cells, it fails to eradicate leukemia-initiating 
cells in CML. In fact, both FoxO activity (Naka et al., 2010) 
and BCL6 expression levels (Fig. 1) are increased by Imatinib, 
which provides a rationale for selective survival of leukemia- 
initiating cells in CML during long-term Imatinib therapy. FoxO 
factors are critical for LIC maintenance in CML-CP, but not 
CML-BC (Naka et al., 2010), and BCL6 inhibition leads to 
the eradication of LICs in CML-CP, but not CML-BC (Fig. 6, 
A–C). Consistent with these findings, both FoxO3A and BCL6 
expression levels are tightly correlated during progression of 
CML-CP toward CML-BC (Fig. S11). We propose that phar-
macological inhibition of BCL6 breaks the quiescence pro-
gram of LICs in CML and renders them vulnerable to drug 
treatment, e.g., through derepression of MYC (Fig. S12) and 
reactivation of the Arf/p53 pathway (Fig. 3 D and Fig. S1). 
Targeting cellular quiescence for selective leukemia stem cell 
eradication was recently proposed based on observations on 
IFN-–, G-CSF–, or As2O3-mediated activation (“awaken-
ing”) of dormant LICs (Essers and Trumpp, 2010; Trumpp   
et al., 2010).
Here, we show that pharmacological inhibition of BCL6 
leads to LIC apoptosis (Fig. S8) and effectively prevents leukemia 
Figure 6.  BCL6-inhibition results in de-
pletion and cell cycle arrest of CD34+ 
CD38 CML cells. Patient-derived leuka-
pheresis samples from 5 patients with CML in 
CP and 1 patient in myeloid blast crisis CML were 
incubated in the presence of RI-BPI or vehicle 
for 2 h, and then washed and incubated with 
cytokines (100 ng/ml SCF, 10 ng/ml G-CSF,  
20 ng/ml FLT3, 20 ng/ml IL-3, and 20 ng/ml IL-6). 
(A) Cells were stained with CD34 and CD38 
cell surface antibodies and analyzed by FACS. 
(B) Cells were stained with CFSE to track cell 
divisions over time. The analysis was gated on 
CD34+ CD38 LICs. (C) Synopsis of the effect of 
2 h RI-BPI treatment on CD34+ CD38 LICs 
(top) and CD34 transient amplifying CML cells 
(bottom) in 5 cases of CML-CP (green lines) 
and 1 case of CML-BC (red line).2172 BCL6 is required for leukemia initiation in CML | Hurtz et al.
3-cm diam dishes, with an extra water supply dish to prevent evaporation. 
After 7–22 d, colony numbers were counted.
Hoechst 33342 staining. Human CML cells were labeled with Hoechst 
33342 according to the protocol from Goodell et al. (1996). In brief, cells 
were suspended in DME (2% FBS and 10 mmol/liter Hepes buffer) and 
Hoechst 33342 dye was added (5 µg/ml, 90 min at 37°C). After the incuba-
tion with Hoechst 33342, cells were centrifuged and resuspended in cold 
Hanks’ balanced saline solution (2% FBS, 10 mM Hepes buffer, room tem-
perature). Propidium iodide was added to the cells before analysis.
CFSE staining. Primary human CML cells were labeled with CFSE (Invit-
rogen) according to the manufacturer’s protocol. Cells were resuspended in 
prewarmed PBS (0.1% BSA) and incubated with 0.5 µM CFSE for 10 min 
at 37°C. Subsequently, 5 volumes of ice-cold PBS were added and cells were 
incubated for 5 min on ice. After the incubation, cells were washed twice 
with cold PBS and then cultured in IMDM, 20% BIT, 100 IU/ml penicillin, 
100 µg/ml streptomycin, 25 µmol/liter -mercaptoethanol, 100 ng/ml SCF, 
100 ng/ml G-CSF, 20 ng/ml FLT3, 20 ng/ml IL-3, and 20 ng/ml IL-6) for 
a maximum of 5 d. CFSE levels were measured by flow cytometry together 
with staining for CD34 and CD38 surface marker expression.
Affymetrix GeneChip analysis. Biotinylated cRNA was generated and 
fragmented according to the Affymetrix protocol and hybridized to either a 
U133A 2.0 human, 430 mouse, or Mouse Gene 1.0 ST microarrays (Affyme-
trix). After scanning (GeneChip Scanner 3000 7G; Affymetrix), the generated 
data files were imported to BRB Array Tool and processed using the robust 
multi-array average algorithm. To determine relative signal intensities, the ra-
tio of intensity for each sample in a probe set was calculated by normalizing 
to the mean value of grouped samples. Microarray data are available from the 
Gene Expression Omnibus (GEO) under accession nos. GSE24814 (STAT5-
deletion;  BCR-ABL1–transformed  prep  cells),  GSE24813  (BCL6+/+  and 
BCL6/ BCR-ABL1–transformed CML-like cells), GSE20987 (BCL6+/+ 
and BCL6/ BCR-ABL1–transformed pre–B ALL cells), and GSE24493 
(Imatinib treated and nontreated human CML cell lines).
Online supplemental material. Supplementary information for this study in-
cludes information on CML patient samples (Table S1), retroviral and lentiviral 
vectors (Table S2), oligonucleotides used (Table S3), telomere length measure-
ment protocol (Table S4), and an overview of genetic mouse mutants studied 
(Table S5). Fig. S1 presents a schematic of BCL6-dependent LIC-survival signal-
ing in CML. Validation of gene expression changes were performed in Figs. S2 
and S3. Fig. S4 shows transformation efficiency of BCL6+/+ and BCL6/ 
hematopoietic progenitor cells. Phenotypic authentication of CML-like leuke-
mia by flow cytometry and RT-PCR and microarray analysis is demonstrated in 
Figs. S5 and S6, respectively. Fig. S7 describes differential gene expression and side 
population phenotypes in BCL6+/+ and BCL6/ CML-like cells. Fig. S8 shows 
increased propensity to apoptosis of BCL6/ CML-like cells. Fig. S9 shows col-
ony formation assays for normal BCL6+/+ and BCL6/ hematopoietic progeni-
tor  cells.  Fig.  S10  summarizes  results  from  telomere  length  measurements.   
Fig. S11 shows a meta-analysis of gene expression values of FoxO3a and BCL6. 
Fig. S12 shows recruitment of BCL6 to cell cycle regulators and the effects of 
BCL6-activation on cell cycle progression. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20110304/DC1.
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BCR-ABL1. Lineage identity of CML-like leukemia cells was authenticated by 
flow cytometry and quantitative RT-PCR (Fig. S5) and microarray analysis 
(Fig. S6). Mouse CML-like cells and human CML cells were then labeled 
with lentiviral firefly luciferase (D.B. Kohn, University of California Los   
Angeles, Los Angeles, CA; Table S2), selected based on antibiotic resistance 
(puromycin), and injected either via intrafemoral or intravenous tail vein in-
jection into sublethally irradiated (300 cGy) NOD/SCID recipient mice. 
Engraftment was monitored using luciferase bioimaging (VIS 100 biolumi-
nescence/optical imaging system; Xenogen). D-Luciferin (Xenogen) dis-
solved in PBS was injected intraperitoneally at a dose of 2.5 mg per mouse 
15 min before measuring the light emission.
Retroviral and lentiviral transduction. Retroviral constructs encoding 
BCR-ABL1  (R. Van  Etten, Tufts  University,  Boston,  MA),  FoxO3A   
(D.A.  Fruman,  University  of  California  Irvine,  Irvine,  CA),  dominant- 
negative BCL6 (DN-BCL6-ERT2), inducible activation of BCL6 (BCL6-
ERT2; A.L. Shaffer and L.M. Staudt, National Cancer Institute, Bethesda, 
MD), Cre-GFP, and empty controls, as well as lentiviral vectors encoding 
firefly luciferase, were used in transduction experiments as described previ-
ously (Duy et al., 2010). A detailed list of vectors and transduction conditions 
is given in Table S2.
Quantitative RT-PCR. Total RNA from cells was extracted using RNeasy 
isolation kit from QIAGEN. cDNA was generated using a poly(dT) oligonu-
cleotide and the SuperScript III Reverse transcription (Invitrogen). Quanti-
tative  real-time  PCR  was  performed  with  the  SYBRGreenER  mix 
(Invitrogen) and the ABI7900HT real-time PCR system (Applied Biosys-
tems)  according  to  standard  PCR  conditions.  Primers  for  quantitative   
RT-PCR are listed in Table S3.
BCL6/, Ptenfl/fl, P53fl/fl, and Stat5a/bfl/fl mice. Bone marrow from 
BCL6/ (R. Dalla-Favera, Columbia University, New York, NY; Ye et al., 
1997; Table S5) and Stat5abfl/fl mice (L. Hennighausen, National Institute of 
Diabetes and Digestive and Kidney Diseases, Bethesda, MD; Liu et al., 1997; 
Table S5) was harvested and hematopoietic progenitor cells were propagated 
as described above. Deletion of Stat5a/bfl/fl, P53fl/fl, and Ptenfl/fl was induced 
by retroviral transduction with Cre-GFP (using a GFP empty vector control). 
Cells were cultured at 37°C in a humidified incubator with 5% CO2. All 
mouse experiments were subject to institutional approval by Children’s Hos-
pital Los Angeles IACUC.
Western blot analysis. Cells were lysed in CelLytic buffer (Sigma-Aldrich) 
supplemented with 1% protease inhibitor cocktail (Thermo Fisher Scien-
tific). 25 µg of protein mixture per sample were separated on NuPAGE   
(Invitrogen) 4–12% Bis-Tris gradient gels and transferred on PVDF membranes 
(Immobilion; Millipore). For the detection of mouse and human proteins by 
Western blot, primary antibodies were used together with the WesternBreeze 
immunodetection system (Invitrogen). The following antibodies were used: 
human BCL6 (clones D8 and N3; Santa Cruz Biotechnology, Inc.), mouse 
BCL6 (rabbit polyclonal; Cell Signaling Technology), Arf (4C6/4; Cell Sig-
naling Technology), p53 (1C12; Cell Signaling Technology), and pan-specific 
anti-phosphotyrosine  (4G10;  Millipore). Antibodies  against  -actin  were 
used as a loading control (H4; Santa Cruz Biotechnology, Inc.).
Flow cytometry. Antibodies against mouse CD44 (IM7), c-kit (2B8), and 
respective isotype controls were purchased from BD. Anti–mouse Sca-1 anti-
body (clone 177228) was obtained from R&D Systems. For apoptosis analy-
ses, annexin V, propidium iodide, and 7-aminoactinomycin D (7AAD) were 
used (BD). Antibodies against human CD34 (563), CD38 (HITZ), and CD90 
(OX-7), as well as respective isotype controls, were purchased from BD.
Colony-forming assay. The methylcellulose colony-forming assays were 
performed with 100,000 normal LSK cells, and BCR-ABL1–transformed 
mouse CML-like cells or 10,000 human CML cells. Cells were resuspended 
in mouse MethoCult medium (StemCell Technologies) and cultured on JEM Vol. 208, No. 11  2173
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